Mark Diehl, DO
Rheumatology · Gettysburg, PANPI 1982667754
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $111,529 of the $121,895 with a category attached, or 91.5%. Amgen accounts for 98.0% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $51,748 and has fallen 76.5% since, to $12,182 in 2025. Among rheumatology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $591.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$120K
- AstraZeneca$720
- GSK$348
- Novartis$219
- Johnson & Johnson$209
- Lilly USA, LLC$198
- plus $699 from 7 others
What the payments were for
- Consulting fees$4830%
- Speaking & faculty fees$111,52991%
- Travel & lodging$3,4443%
- Food & beverage$6,1975%
- Education$2430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 167 | $119,502 |
| AstraZeneca | 8 | $720 |
| GSK | 3 | $348 |
| Novartis | 5 | $219 |
| Johnson & Johnson | 3 | $209 |
| Lilly USA, LLC | 3 | $198 |
| Pfizer | 8 | $177 |
| AbbVie | 2 | $148 |
| UCB, Inc. | 2 | $140 |
| Janssen Scientific Affairs, LLC | 1 | $125 |
| Aurinia Pharma U.S., Inc. | 2 | $73 |
| Grifols Shared Services North America, Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$121,895 in reported general payments places this provider in the 90th percentile of 351 rheumatology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 158 | $1,225,607 |
| Humira(Cf) PenAdalimumab | 84 | $748,702 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 46 | $505,244 |
| OtezlaApremilast | 91 | $486,737 |
| TremfyaGuselkumab | 22 | $301,039 |
| Cosentyx Unoready PenSecukinumab | 23 | $260,273 |
| Taltz AutoinjectorIxekizumab | 34 | $230,211 |
| Xeljanz XrTofacitinib Citrate | 31 | $172,847 |
| Cimzia (2 Pack)Certolizumab Pegol | 19 | $135,926 |
| XeljanzTofacitinib Citrate | 24 | $129,102 |
| Enbrel MiniEtanercept | 15 | $108,419 |
| Orencia ClickjectAbatacept | 18 | $100,732 |
| Humira(Cf)Adalimumab | 13 | $87,254 |
| Humira PenAdalimumab | 12 | $81,738 |
| SimponiGolimumab | 13 | $77,824 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Prolia, Rayos | $119,502 | $547,301121 claims |
| Johnson & JohnsonTremfya, Simponi | $209 | $378,86235 claims |
| UCB, Inc.Cimzia (2 Pack) | $140 | $135,92619 claims |
| PfizerXeljanz | $177 | $129,10224 claims |
| AbbVieHumira(Cf) | $148 | $87,25413 claims |
| Radius Health, Inc.Tymlos | $15 | $41,34916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 351 rheumatology providers in Pennsylvania.
Other rheumatology in Gettysburg
- Alan EpsteinPhiladelphia$1.2M
- Lawrence LeventhalHuntingdon Valley$1.1M
- Alan KivitzDuncansville$936K
- Paula HerringNewtown Square$920K
- Rohit AggarwalPittsburgh$810K
- Frederick MurphyDuncansville$494K
- Peter MerkelRadnor$479K
- Martin BergmanRidley Park$458K
- Alexis Ogdie-BeattyPhiladelphia$433K
- Ellen FieldBethlehem$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.